These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 15195003

  • 1. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, Mannazzu M, Falchi A, Mura MS, Madeddu G.
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
    [Abstract] [Full Text] [Related]

  • 2. Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy.
    Madeddu G, Spanu A, Chessa F, Calia GM, Lovigu C, Mannazzu M, Falchi A, Sanna D, Mura MS, Madeddu G.
    Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):290-301. PubMed ID: 18596668
    [Abstract] [Full Text] [Related]

  • 3. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
    Madeddu G, Spanu A, Solinas P, Babudieri S, Calia GM, Lovigu C, Mannazzu M, Nuvoli S, Piras B, Bagella P, Mura MS, Madeddu G.
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
    [Abstract] [Full Text] [Related]

  • 4. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.
    Seminari E, Castagna A, Soldarini A, Galli L, Fusetti G, Dorigatti F, Hasson H, Danise A, Guffanti M, Lazzarin A, Rubinacci A.
    HIV Med; 2005 May; 6(3):145-50. PubMed ID: 15876279
    [Abstract] [Full Text] [Related]

  • 5. BMD is reduced in HIV-infected men irrespective of treatment.
    Amiel C, Ostertag A, Slama L, Baudoin C, N'Guyen T, Lajeunie E, Neit-Ngeilh L, Rozenbaum W, De Vernejoul MC.
    J Bone Miner Res; 2004 Mar; 19(3):402-9. PubMed ID: 15040828
    [Abstract] [Full Text] [Related]

  • 6. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
    Su YB, Xie J, Han Y, Qiu ZF, Li YL, Song XJ, Yu W, Li TS.
    Zhonghua Yi Xue Za Zhi; 2012 May 08; 92(17):1155-8. PubMed ID: 22883000
    [Abstract] [Full Text] [Related]

  • 7. Low-level lifetime exposure to cadmium decreases skeletal mineralization and enhances bone loss in aged rats.
    Brzóska MM, Moniuszko-Jakoniuk J.
    Bone; 2004 Nov 08; 35(5):1180-91. PubMed ID: 15542044
    [Abstract] [Full Text] [Related]

  • 8. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.
    Clin Infect Dis; 2005 Dec 01; 41(11):1662-70. PubMed ID: 16267741
    [Abstract] [Full Text] [Related]

  • 9. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
    Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D, ANRS 121 Hippocampe study group.
    AIDS; 2009 Apr 27; 23(7):817-24. PubMed ID: 19363330
    [Abstract] [Full Text] [Related]

  • 10. Potential predictive factors of osteoporosis in HIV-positive subjects.
    Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabò EV, Melzi S, Bini T, Sardanelli F, Cornalba G, Monforte Ad.
    Bone; 2006 Jun 27; 38(6):893-7. PubMed ID: 16377270
    [Abstract] [Full Text] [Related]

  • 11. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
    Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR.
    Clin Endocrinol (Oxf); 2007 Aug 27; 67(2):270-5. PubMed ID: 17547686
    [Abstract] [Full Text] [Related]

  • 12. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
    van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, Sutinen J, Ristola M, Danner SA, Reiss P.
    AIDS; 2009 Jul 17; 23(11):1367-76. PubMed ID: 19424051
    [Abstract] [Full Text] [Related]

  • 13. Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are at high risk for abnormalities in glucose metabolism - a reason for glycemic control.
    Blass SC, Ellinger S, Vogel M, Ingiliz P, Spengler U, Stehle P, von Ruecker A, Rockstroh JK.
    Eur J Med Res; 2008 May 26; 13(5):209-14. PubMed ID: 18559303
    [Abstract] [Full Text] [Related]

  • 14. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J, Rickenbach M, Weber R, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC.
    Antivir Ther; 2005 May 26; 10(1):73-81. PubMed ID: 15751765
    [Abstract] [Full Text] [Related]

  • 15. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
    Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, Timpone J.
    J Clin Endocrinol Metab; 2004 Mar 26; 89(3):1200-6. PubMed ID: 15001610
    [Abstract] [Full Text] [Related]

  • 16. Elevation of intact parathyroid hormone level is a risk factor for low bone mineral density in pretransplant patients with liver diseases.
    Bai XL, Liang TB, Wu LH, Li DL, Geng L, Wang WL, Shen Y, Zhang M, Zheng SS.
    Transplant Proc; 2007 Dec 26; 39(10):3182-5. PubMed ID: 18089348
    [Abstract] [Full Text] [Related]

  • 17. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
    Bolland MJ, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Gamble GD, Reid IR.
    Clin Endocrinol (Oxf); 2012 May 26; 76(5):643-8. PubMed ID: 22040002
    [Abstract] [Full Text] [Related]

  • 18. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA.
    AIDS; 2007 Nov 30; 21(18):2473-82. PubMed ID: 18025884
    [Abstract] [Full Text] [Related]

  • 19. Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study.
    Madeddu G, Spanu A, Chessa F, Calia GM, Lovigu C, Solinas P, Mannazzu M, Falchi A, Mura MS, Madeddu G.
    Clin Endocrinol (Oxf); 2006 Apr 30; 64(4):375-83. PubMed ID: 16584508
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of bone mineral density in Iranian HIV/AIDS patients.
    Badie BM, Soori T, Kheirandish P, Izadyar S, SeyedAlinagh S, Foroughi M, Rostamian A, Mohraz M.
    Acta Med Iran; 2011 Apr 30; 49(7):460-7. PubMed ID: 21960080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.